Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
euroPLX 90 LisboneuroPLX 90 Lisbon
Not Confirmed
Not Confirmed
02-03 March, 2026
BIO CEO & InvestorBIO CEO & Investor
Not Confirmed
Not Confirmed
02-03 March, 2026
Clinical OutsourcingClinical Outsourcing
Not Confirmed
Not Confirmed
03-04 March, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
euroPLX 90 LisboneuroPLX 90 Lisbon
Industry Trade Show
Not Confirmed
02-03 March, 2026
BIO CEO & InvestorBIO CEO & Investor
Industry Trade Show
Not Confirmed
02-03 March, 2026
Clinical OutsourcingClinical Outsourcing
Industry Trade Show
Not Confirmed
03-04 March, 2026
Digital content

25 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260224469853/en/PureTech-to-Present-at-the-Leerink-Partners-Global-Healthcare-Conference

19 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260219184180/en/PureTech-Announces-Orphan-Drug-Designations-Granted-by-the-U.S.-Food-and-Drug-Administration-and-European-Commission-for-Deupirfenidone-LYT-100-in-Idiopathic-Pulmonary-Fibrosis

06 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260106445413/en/PureTech-to-Present-at-44th-Annual-J.P.-Morgan-Healthcare-Conference

18 Dec 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-12-18/puretech-appoints-robert-lyne-as-chief-executive-officer

08 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251207891734/en/PureTech-Announces-Successful-End-of-Phase-2-Meeting-with-FDA-for-Deupirfenidone-LYT-100-in-Idiopathic-Pulmonary-Fibrosis

05 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251205523069/en/PureTechs-Founded-Entity-Gallop-Oncology-Announces-Positive-Initial-Topline-Data-from-Phase-1b-Trial-of-LYT-200-in-RelapsedRefractory-Acute-Myeloid-Leukemia-and-High-Risk-Myelodysplastic-Syndrome
ABOUT THIS PAGE